Humanigen Inc (fka HGENQ)

[10nisman]

"ACTIV-5/BET-B may provide prospective validation for lenzilumab in the treatment of COVID-19," said Cameron Durrant, MD, Chief Executive Officer, Humanigen. "We believe ACTIV-5/BET-B, along with LIVE-AIR, will provide the sufficient size and statistical power typically required for a BLA to be submitted to FDA."

This is Cameron telling the street their discussions with the FDA have lead to no EUA approval and HGEN needed to expand the ACTIV-5 trial size in hopes of having enough support for the BLA.

July has come and gone and HGEN is trading at $16. Time to shutdown production...